Literature DB >> 312784

Structure-activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio.

G E Adams, E D Clarke, P Gray, R S Jacobs, I J Stratford, P Wardman, M E Watts, J Parrick, R G Wallace, C E Smithen.   

Abstract

This paper describes measurements of the aerobic cytotoxicity of 42 nitroaromatic and nitroheterocyclic compounds towards Chinese Hamster cells in vitro. The results of acute and chronic exposure were quantified, and the concentration C required to achieve a standard response estimated. Fitting the data to an equation of the form - log C = b0 + b1E, where E is the one-electron reduction potential, explained 47 and 71 per cent of the variance in the acute and chronic aerobic cytotoxicity respectively. The addition of further terms to the equation, quantifying partition properties, was not statistically significant. The coefficient b1 was similar for both acute and chronic exposure; the dependence of both cytotoxicity and radiosensitization efficiency on reduction potential was also similar. A therapeutic ratio derived from these in vitro measurements showed no dependence on redox or partition properties. The insensitivity of cytotoxicity and radiosensitization properties to variations in molecular structure, other than those which influence redox behaviour, offers exceptional flexibility in developing compounds of improved therapeutic ratio.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 312784     DOI: 10.1080/09553007914550161

Source DB:  PubMed          Journal:  Int J Radiat Biol Relat Stud Phys Chem Med        ISSN: 0020-7616


  9 in total

1.  Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5.

Authors:  J Matthews; H Adomat; N Farrell; P King; C Koch; E Lord; B Palcic; N Poulin; J Sangulin; K Skov
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia.

Authors:  Blake A Winn; Zhe Shi; Graham J Carlson; Yifan Wang; Benson L Nguyen; Evan M Kelly; R David Ross; Ernest Hamel; David J Chaplin; Mary L Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem Lett       Date:  2016-12-01       Impact factor: 2.823

3.  Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.

Authors:  P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis.

Authors:  S N Moreno; R Docampo
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

5.  Comparative studies of hypoxic-cell radiosensitization using artificially hypoxic skin in vivo.

Authors:  J Denekamp; B D Michael; A I Minchinton; C E Smithen; F A Stewart; M R Stratford; N H Terry
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

6.  Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.

Authors:  G E Adams; I Ahmed; P W Sheldon; I J Stratford
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

7.  A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo.

Authors:  J Overgaard; M Overgaard; O S Nielsen; A K Pedersen; A R Timothy
Journal:  Br J Cancer       Date:  1982-12       Impact factor: 7.640

8.  Cytotoxic properties of a 4-nitroimidazole (NSC 38087): a radiosensitizer of hypoxic cells in vitro.

Authors:  I J Stratford; C Williamson; C Hardy
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

9.  Interaction of nitroimidazole drugs with DNA in vitro: structure-activity relationships.

Authors:  R J Knox; R C Knight; D I Edwards
Journal:  Br J Cancer       Date:  1981-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.